For press inquiries click here to contact us.
Oric Pharmaceuticals, Inc.
New exec team, new money and a big syndicate — ORIC heads to PhII
insitro
Biotech Insitro boosts executive team with Aimmune development chief and Pfizer vet
Adaptive Biotechnologies Corporation (Alumni)
Adaptive Biotechnologies stock soars 90% after ringing Nasdaq opening bell following $300M IPO
Inscripta (Alumni)
Inscripta Looks to Combine CRISPR, Single-Cell Genomics, Synthetic Biology in New Platform
insitro
With $150M and a new NASH discovery deal with Gilead, AI star Daphne Koller has set out to change the drug R&D world
Alder Biopharmaceuticals, Inc.
Alder BioPharmaceuticals raises $170M in stock offering as FDA reviews its migraine therapy
Audentes Therapeutics (Alumni)
Audentes Therapeutics to develop gene therapies for two types of muscular dystrophy, including Duchenne
Xconomy
With $191M Haul, Maze Therapeutics Takes Aim at Genetic Diseases
Xconomy
Peloton Therapeutics Raises $150M to Advance Kidney Cancer Therapy
Please see important disclaimers in the Terms section.
